<DOC>
	<DOCNO>NCT01303445</DOCNO>
	<brief_summary>The objective current study investigate drug-drug interaction occur administration omeprazole 80 mg q.d . steady state pharmacokinetics dipyridamole pharmacodynamics ASA-induced platelet aggregation inhibition ( component Aggrenox® ) administer every 12 hour steady state .</brief_summary>
	<brief_title>Drug-drug Interaction Study Aggrenox Omeprazole Normal Volunteers</brief_title>
	<detailed_description>Purpose :</detailed_description>
	<mesh_term>Omeprazole</mesh_term>
	<mesh_term>Aspirin , Dipyridamole Drug Combination</mesh_term>
	<criteria>Inclusion criterion : 1 . Healthy male female accord follow criterion : Based upon complete medical history , include physical examination , vital sign ( blood pressure ( BP ) , pulse rate ( PR ) ) , 12lead ECG , clinical laboratory test 2 . BMI &gt; 18.5 BMI &lt; 32 kg/m2 ( Body Mass Index ) Exclusion criterion : 1 . Any finding medical examination ( include BP , PR ECG ) deviate normal clinical relevance opinion PI 2 . Any evidence clinically relevant concomitant disease 3 . Clinically significant gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological , hormonal , hematologic ( include history abnormal bruising ) disorder opinion PI 4 . Surgery gastrointestinal tract might impair drug absorption 5 . Clinically significant diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder 6 . History relevant orthostatic hypotension , faint spell blackout . 7 . Chronic relevant acute infection 8 . History relevant allergy/hypersensitivity ( include allergy study drug excipients , reaction relate drug [ e.g. , nonsteroidal antiinflammatory drug ] ) 9 . Intake drug long halflife ( ¿24 hour ) within one month , less 10 half life respective drug , prior study drug administration trial 10 . Use drug might reasonably influence result trial ( include OTC antacid ) base knowledge time protocol preparation within 14 day prior administration trial 11 . Participation another trial investigational drug within two month prior administration trial 12 . Tobacco use within 90 day prior checkin throughout study 13 . Alcohol abuse within past 2 year 14 . Drug abuse within past 2 year 15 . Blood donation significant blood loss within 56 day ( inclusive ) prior screen , plasma donation within 7 day ( inclusive ) prior study drug administration , trial 16 . Excessive physical activity ( within one week prior first drug administration trial ) 17 . Any laboratory value outside reference range clinical relevance opinion PI ; include positive virology , urine drug screen , positive fecal occult blood test 18 . Inability comply dietary regimen trial site 19 . In opinion investigator would best interest subject exclude participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>